LOGICS had an open-label dose titration and maintenance phase for up to 19 weeks, followed by an 8-week double-blind, placebo controlled, randomized withdrawal phase and 8 weeks of double-blind restoration.1,2
The proportion of patients with mUFC normalization, defined as a patient with mUFC at or below the ULN at the end of randomized withdrawal phase without meeting a requirement for early rescue during the randomized withdrawal phase.
BID=twice daily; mUFC=mean urinary free cortisol; ULN=upper limit of normal.
References: 1. Recorlev. Prescribing Information. Xeris Pharmaceuticals, Inc; 2021. 2. Data on file. Xeris Pharmaceuticals, Inc. 2021.